دورية أكاديمية
أعرض في EDS

Eosinophilic Esophagitis: The Role of Steroids and the Dose, Duration, and Delivery of Steroid Therapy.

التفاصيل البيبلوغرافية
العنوان: Eosinophilic Esophagitis: The Role of Steroids and the Dose, Duration, and Delivery of Steroid Therapy.
المؤلفون: Ramanan SP; Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.; Medicine/Surgery, Saveetha Medical College, Chennai, IND.; Internal Medicine, Henry Ford Health System, Jackson, USA., Singh B; Internal Medicine, Henry Ford Health System, Jackson, USA., Gandhamaneni SH; Internal Medicine, Saveetha Medical College, Chennai, IND., Sange I; Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.; Internal Medicine, Karamshibhai Jethabhai Somaiya Medical College, Hospital & Research Center, Mumbai, IND.
المصدر: Cureus [Cureus] 2024 Apr 15; Vol. 16 (4), pp. e58343. Date of Electronic Publication: 2024 Apr 15 (Print Publication: 2024).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Cureus, Inc Country of Publication: United States NLM ID: 101596737 Publication Model: eCollection Cited Medium: Print ISSN: 2168-8184 (Print) Linking ISSN: 21688184 NLM ISO Abbreviation: Cureus Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Palo Alto, CA : Cureus, Inc.
مستخلص: Eosinophilic esophagitis (EoE) is a chronic immune-mediated condition characterized by the eosinophil infiltration of the esophagus (>15 per high power field). Recently, there has been an increase in both the incidence and prevalence of the disease. The common modalities of treatment are dietary modification, proton pump inhibitors, and steroids. However, the United States Food and Drug Administration has not approved any drugs for the treatment of EoE. This review has discussed the role of steroids in the treatment of EoE, focusing on the various formulations of the drug, its dosage, drug delivery, and duration of therapy. The study also covers the common outcomes of steroid therapy and its side effects.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright © 2024, Ramanan et al.)
References: Gut. 2016 Mar;65(3):390-9. (PMID: 25792708)
Gastroenterology. 2019 Jul;157(1):74-86.e15. (PMID: 30922997)
United European Gastroenterol J. 2017 Apr;5(3):335-358. (PMID: 28507746)
Gastroenterology. 2014 Aug;147(2):324-33.e5. (PMID: 24768678)
Dig Dis Sci. 2019 Jun;64(6):1571-1578. (PMID: 30659470)
Dig Dis Sci. 2016 Oct;61(10):2928-2934. (PMID: 27250980)
N Engl J Med. 2004 Aug 26;351(9):940-1. (PMID: 15329438)
J Allergy Clin Immunol Pract. 2013 Jul-Aug;1(4):332-40; quiz 341-2. (PMID: 24565538)
J Allergy Clin Immunol. 2014 Nov;134(5):1084-1092.e1. (PMID: 25258143)
Gastroenterology. 2020 Nov;159(5):1672-1685.e5. (PMID: 32721437)
Gastroenterology. 2017 Mar;152(4):776-786.e5. (PMID: 27889574)
Gastroenterology. 2018 Jan;154(2):319-332.e3. (PMID: 28774845)
Aliment Pharmacol Ther. 2017 Aug;46(4):401-409. (PMID: 28639700)
Gastroenterology. 2012 Aug;143(2):321-4.e1. (PMID: 22561055)
J Allergy Clin Immunol. 2005 Dec;116(6):1206-12. (PMID: 16337447)
Gastroenterology. 2018 Jan;154(2):346-359. (PMID: 28756235)
J Pediatr Gastroenterol Nutr. 2009 Jan;48(1):30-6. (PMID: 19172120)
J Pediatr Gastroenterol Nutr. 1998 Apr;26(4):380-5. (PMID: 9552132)
Nat Rev Immunol. 2013 Jan;13(1):9-22. (PMID: 23154224)
Am J Gastroenterol. 2016 Aug;111(8):1187-97. (PMID: 27325220)
J Allergy Clin Immunol. 2012 May;129(5):1419-21. (PMID: 22480537)
Gastroenterology. 2006 Nov;131(5):1381-91. (PMID: 17101314)
J Pharmacol Exp Ther. 2004 Apr;309(1):249-58. (PMID: 14718604)
J Biol Chem. 2011 Apr 15;286(15):13193-204. (PMID: 21325281)
J Pediatr Gastroenterol Nutr. 1998 Jul;27(1):90-3. (PMID: 9669733)
Gastroenterology. 2013 Dec;145(6):1230-6.e1-2. (PMID: 23954315)
Clin Gastroenterol Hepatol. 2005 Dec;3(12):1198-206. (PMID: 16361045)
J Allergy Clin Immunol. 2011 Jul;128(1):3-20.e6; quiz 21-2. (PMID: 21477849)
Am J Gastroenterol. 2018 Jun;113(6):836-844. (PMID: 29700481)
Gastroenterology. 2019 Jul;157(1):65-73.e5. (PMID: 30872104)
Mucosal Immunol. 2015 May;8(3):464-75. (PMID: 25807184)
Drugs R D. 2020 Dec;20(4):359-367. (PMID: 33057953)
Aliment Pharmacol Ther. 2012 Nov;36(10):950-8. (PMID: 22994460)
Clin Gastroenterol Hepatol. 2009 Oct;7(10):1055-61. (PMID: 19577011)
Biochem Pharmacol. 2007 May 15;73(10):1657-64. (PMID: 17331475)
Clin Gastroenterol Hepatol. 2019 Mar;17(4):666-673.e8. (PMID: 29902649)
Am J Gastroenterol. 2013 May;108(5):679-92; quiz 693. (PMID: 23567357)
فهرسة مساهمة: Keywords: budesonide; ciclesonide; eosinophilic esophagitis; fluticasone; steroids
تواريخ الأحداث: Date Created: 20240517 Latest Revision: 20240518
رمز التحديث: 20240518
مُعرف محوري في PubMed: PMC11097238
DOI: 10.7759/cureus.58343
PMID: 38756322
قاعدة البيانات: MEDLINE
الوصف
تدمد:2168-8184
DOI:10.7759/cureus.58343